Thumb-ECG Ambulant Screening for Atrial Fibrillation in Patients Treated for Hyperthyroidism (TAMBOURINE)
Launched by KAROLINSKA INSTITUTET · Sep 13, 2013
Trial Information
Current as of June 14, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient is deemed suitable for treatment with radioiodine or antithyroid drugs
- • Patient has a thyreotropin (TSH) value below 0,1 mIU/L, measured less than 2 weeks before inclusion
- • Patient has a CHADS-VASc-score of 1 point or higher (excluding if 1 point is for female sex only)
- • Patient gives written consent to participate in study
- Exclusion Criteria:
- • Patient has a previously known diagnosis of atrial fibrillation
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gothemburg, , Sweden
Stockholm, , Sweden
Stockholm, , Sweden
Patients applied
Trial Officials
Mårten Rosenqvist, Prof
Study Chair
Karolinska Institutet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials